Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Vasogen-- VAS on TSE -- Ignore unavailable to you. Want to Upgrade?

To: Done, gone. who wrote (376)	12/20/2007 7:52:29 PM
From: Stephen O	Respond to of 377

Vasogen is not dead and buried, probably best performing stock on TSX over the past month. Here's latest news release: Results of Vasogen's Phase III ACCLAIM Trial Accepted for Publication in The Lancet By PR Newswire Last Updated: 12/18 07:00AM MISSISSAUGA, ON, Dec. 18 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today announced that the results from the phase III ACCLAIM trial of its Celacade(TM) System in patients with chronic heart failure have been accepted for publication in The Lancet, a world-leading medical journal. As previously reported by Vasogen, a key finding from the ACCLAIM trial was a 39% reduction in the risk of death or cardiovascular hospitalizations for a large pre-specified subgroup of patients with NYHA Class II heart failure who received Vasogen's Celacade therapy, compared to patients receiving placebo. "We believe that the publication of the ACCLAIM results, in a journal renowned for the communication of high-quality peer-reviewed research from around the world, is indicative of the exceptional design and execution of the trial, as well as the important contribution of ACCLAIM in identifying the role of Celacade in the treatment of patients suffering from heart failure," commented Chris Waddick, President and CEO of Vasogen. "The results published in Lancet will help to underpin the recently announced commercial launch of Celacade in the European Union, where it has already been approved, as well as the initiation of the ACCLAIM-II trial, which is a confirmatory trial in NYHA Class II patients being planned for the purpose of achieving regulatory approval in the United States." The manuscript detailing the results of Vasogen's phase III ACCLAIM trial of Celacade in patients with chronic heart failure is authored by Guillermo Torre-Amione, Methodist Hospital, Houston, TX; Stefan D Anker, Charite, Campus Virchow-Klinikum, Berlin, Germany; Robert C Bourge, University of Alabama at Birmingham, Birmingham, AL; Wilson S Colucci, Boston University School of Medicine, Boston, MA; Barry H Greenberg, UCSD Medical Center, San Diego, CA; Per Hildebrandt, Frederiksberg Hospital, Frederiksberg, Denmark; Andre Keren, Hadassah University Hospital, Jerusalem, Israel; Michael Motro, Chaim Sheba Medical Center, Tel-Hashomer, Israel; Lemuel A Moye, University of Texas Health Science Center, Houston, TX; Jan Erik Otterstad, Hospital of Vestfold, Toensberg, Norway; Craig M Pratt, Methodist Hospital, Houston, TX; Piotr Ponikowski, Military Hospital, Wroclaw, Poland; Jean Lucien Rouleau, Faculty of Medicine, Universite de Montreal, Montreal, PQ; Francois Sestier, Hotel Dieu du CHUM, Center de Recherche, Montreal, PQ; Bernhard R Winkelmann, Kardiologische Gemeinschaftspraxis, Frankfurt, Germany; and James B Young, The Cleveland Clinic, Cleveland, OH. The Lancet's coverage is international in focus and extends to all aspects of human health. It aims to publish the best original primary research papers, and review articles of the highest standard. The Lancet is stringently edited and peer-reviewed to ensure the scientific merit and clinical relevance of its diverse content. Drawing on an international network of advisers and contributors, The Lancet meets the needs of physicians by adding to their clinical knowledge and alerting them to current issues affecting the practice of medicine worldwide. About Vasogen: Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is being marketed in the EU by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage clinical development for the treatment of chronic heart failure in the United States. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class.